Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate

Launched by HOPE PHARMACEUTICALS · Oct 20, 2017

Keywords

ClinConnect Summary

This is an 8-week observational follow-up study of patients who participated in the ST-001 CALISTA study. In this ST-003 (OF-CALISTA) study, the occurrence of delayed adverse events, standard of care treatments for calciphylaxis (medications \[including Sodium Thiosulfate Injection and pain medication\], wound debridement, amputation, hyperbaric oxygen therapy, and surgical parathyroidectomy), and calciphylaxis-related complications (new or worsening skin lesions, ulceration, infection, sepsis and hospitalizations) will be recorded during an 8-week observation period following patient parti...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Previously enrolled as a patient in ST-001 CALISTA study
• • Willing to provide written informed consent
• • Willing and able to adhere to all study-related procedures
• • Willing to authorize release of medical records
• • Willing to authorize collection of medical data from health care providers
• • Provide email, home address and phone number where he/she can be reached
• Exclusion Criteria:
• • • Patient did not participate in ST-001 CALISTA study